Medical University Of Lausitz Carl Thiem
- Address
- lock Available on a paid plan
Medical University Of Lausitz Carl Thiem - Oncology & Hematology Research
The Medical University of Lausitz Carl Thiem is a specialized clinical research center focused on advancing treatment protocols for complex oncological and hematological malignancies. The center demonstrates particular expertise in developing innovative therapeutic strategies for both pediatric and adult cancer populations, with emphasis on optimizing treatment efficacy while minimizing toxicity.
- Pediatric hematologic malignancies including myeloid leukemia in children with Down Syndrome
- Hormone receptor-positive, HER2-negative early breast cancer with focus on treatment de-escalation strategies
- Targeted therapy approaches combining CDK4/6 inhibitors with endocrine therapy in intermediate-risk breast cancer
The institution's research portfolio reflects a commitment to personalized medicine approaches, conducting Phase III clinical trials that evaluate both novel drug combinations and chemotherapy de-escalation protocols. Their work in adjuvant breast cancer treatment investigates non-inferiority strategies using ribociclib combined with endocrine therapy, aiming to reduce treatment burden for patients with intermediate-risk disease. Additionally, their pediatric oncology program explores advanced formulations like CPX-351 for children with specific genetic conditions, demonstrating the center's comprehensive approach to improving outcomes across diverse patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 54 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 52 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical University Of Lausitz Carl Thiem
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1 Study of AIR-001 in Adults with Alpha-1 Antitrypsin Deficiency | Airna Corp. | Phase I | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 54 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bortezomib | 3 | Unknown | 2023-03-07 | 2026-07-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.